• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

每日两次及四次齐多夫定对疾病控制中心II/III期患者p24抗原血症的影响。

The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients.

作者信息

Gill S, Tang A, Cordery M, Spacey B, Kelly G, Bateman N T, Barlow D

机构信息

Department of GU Medicine, St Thomas' Hospital, London.

出版信息

Genitourin Med. 1991 Feb;67(1):15-7. doi: 10.1136/sti.67.1.15.

DOI:10.1136/sti.67.1.15
PMID:1680791
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1194606/
Abstract

Reduction of HIV p24 antigenaemia by zidovudine was investigated in 34 HIV antibody-positive, asymptomatic patients in a randomised, double-blind, placebo-controlled trial. Zidovudine was shown to lower p24 antigen levels as effectively when administered twice daily as when administered four times daily. Serum levels of p24 antigen varied little over 18 weeks in patients taking placebo.

摘要

在一项随机、双盲、安慰剂对照试验中，对34名HIV抗体阳性的无症状患者研究了齐多夫定降低HIV p24抗原血症的效果。结果显示，齐多夫定每日给药两次与每日给药四次时降低p24抗原水平的效果相同。服用安慰剂的患者在18周内p24抗原的血清水平变化不大。

相似文献

1
The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients.每日两次及四次齐多夫定对疾病控制中心II/III期患者p24抗原血症的影响。
Genitourin Med. 1991 Feb;67(1):15-7. doi: 10.1136/sti.67.1.15.
2
Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).对有艾滋病进展高风险的无症状HIV感染受试者每日两次服用齐多夫定：一项随机、双盲、安慰剂对照研究。欧洲-澳大利亚协作组（研究017）
AIDS. 1994 Mar;8(3):313-21. doi: 10.1097/00002030-199403000-00004.
3
Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group.1型人类免疫缺陷病毒感染的无症状血友病患者每日两次服用齐多夫定的随机双盲、安慰剂对照试验。欧洲-澳大利亚血友病协作研究组
Br J Haematol. 1994 Jan;86(1):174-9. doi: 10.1111/j.1365-2141.1994.tb03270.x.
4
Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.齐多夫定联合α干扰素与单用齐多夫定治疗CD4+细胞计数>150×10⁶/L的有症状或无症状HIV感染者：Zidon试验结果。Zidon研究组
AIDS. 1995 Sep;9(9):1025-35.
5
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.齐多夫定用于无症状人类免疫缺陷病毒感染。对每立方毫米CD4阳性细胞少于500个的患者进行的对照试验。美国国立过敏与传染病研究所艾滋病临床试验组。
N Engl J Med. 1990 Apr 5;322(14):941-9. doi: 10.1056/NEJM199004053221401.
6
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.拉米夫定与齐多夫定联合疗法在曾接受齐多夫定治疗患者中的安全性和疗效。与齐多夫定单药疗法的随机对照比较。欧洲拉米夫定艾滋病工作小组
JAMA. 1996 Jul 10;276(2):111-7.
7
The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDS-related complex.
AIDS. 1992 Aug;6(8):821-5. doi: 10.1097/00002030-199208000-00009.
8
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.N-丁基-脱氧野尻霉素（SC-48334）与齐多夫定联合用药对HIV-1感染且CD4细胞计数为200 - 500个/mm³患者的安全性和有效性。
J Acquir Immune Defic Syndr (1988). 1994 Feb;7(2):139-47.
9
p24 antigenaemia as a predictor of good immunological responsiveness to zidovudine therapy in asymptomatic HIV infection.p24抗原血症作为无症状HIV感染患者对齐多夫定治疗良好免疫反应性的预测指标。
AIDS. 1992 Mar;6(3):338-9.
10
Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.在接受齐多夫定短期治疗的无症状个体中，无论是否进展为艾滋病，血清中1型人类免疫缺陷病毒RNA与p24抗原水平的明显变化。
AIDS Res Hum Retroviruses. 1995 Apr;11(4):473-9. doi: 10.1089/aid.1995.11.473.

引用本文的文献

1
Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy.抗逆转录病毒联合疗法中药物数量增加的证据的系统评价和荟萃分析。
BMJ. 2002 Mar 30;324(7340):757. doi: 10.1136/bmj.324.7340.757.
2
Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.齐多夫定：关于其用于人类免疫缺陷病毒患者的药物经济学和生活质量考量的综述
Pharmacoeconomics. 1993 Apr;3(4):309-37. doi: 10.2165/00019053-199303040-00006.

本文引用的文献

1
Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine.
Ann Intern Med. 1988 Mar;108(3):372-6. doi: 10.7326/0003-4819-108-3-372.
2
Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.齐多夫定对血清人类免疫缺陷病毒核心抗原水平的影响。一项安慰剂对照试验的结果。
Arch Intern Med. 1988 Oct;148(10):2151-3.
3
Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).获得性免疫缺陷综合征（艾滋病）中的人类免疫缺陷病毒（HIV）抗原血症（p24）以及齐多夫定（AZT）治疗的效果。
Ann Intern Med. 1988 Feb;108(2):175-80. doi: 10.7326/0003-4819-108-2-175.
4
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.持续的HIV抗原血症以及与向艾滋病转变相关的HIV核心抗体下降。
Br Med J (Clin Res Ed). 1986 Dec 6;293(6560):1459-62. doi: 10.1136/bmj.293.6560.1459.
5
Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects.齐多夫定对无症状受试者血清人类免疫缺陷病毒抗原水平的影响。
Lancet. 1988 Feb 20;1(8582):373-6. doi: 10.1016/s0140-6736(88)91179-8.
6
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.3'-叠氮-2',3'-双脱氧胸苷（齐多夫定）及相关双脱氧核苷的临床药理学
N Engl J Med. 1989 Sep 14;321(11):726-38. doi: 10.1056/NEJM198909143211106.
7
Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.齐多夫定相关副作用的性质、时间进程及剂量依赖性：加拿大多中心叠氮胸苷试验结果
AIDS. 1989 Sep;3(9):555-61. doi: 10.1097/00002030-198909000-00001.
8
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.齐多夫定（AZT）治疗轻度症状的1型人类免疫缺陷病毒（HIV）感染患者的安全性和有效性。一项双盲、安慰剂对照试验。艾滋病临床试验组。
Ann Intern Med. 1990 May 15;112(10):727-37. doi: 10.7326/0003-4819-112-10-727.
9
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.齐多夫定用于无症状人类免疫缺陷病毒感染。对每立方毫米CD4阳性细胞少于500个的患者进行的对照试验。美国国立过敏与传染病研究所艾滋病临床试验组。
N Engl J Med. 1990 Apr 5;322(14):941-9. doi: 10.1056/NEJM199004053221401.